SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras steep post-IPO selloff dominates discussion, with traders citing successive insider and IPO lockup share releases and a TD Cowen price-target cut, alongside concerns about OpenAI customer concentration, Nvidia competition, and the companys ability to scale. Bears see continued selling pressure and execution risks, while bulls argue the stock is oversold and point to its cash position, backlog, and wafer-scale technology.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs steep decline to new lows is being discussed alongside concerns about Trumps falling approval and the approaching midterms, with traders also pointing to weak business fundamentals and Truth Social engagement. The conversation is overwhelmingly bearish, though some see the selloff as a potential trading opportunity.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves sharp selloff has focused discussion on its heavy debt, costly financing needs and insider selling, alongside concerns about broader weakness in AI infrastructure stocks. Traders are split between fears of dilution or default and hopes that contracted AI demand, analyst support and buying near recent lows could underpin a recovery.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS CEO Angelos Stergious 15th-anniversary LinkedIn post prompted speculation that its next chapter language hinted at REGAL trial news or a buyout, while skeptics viewed it as routine reassurance. The main focus remains the blinded Phase 3 REGAL trial, last publicly reported at 78 of the 80 deaths needed to trigger final analysis; neither the outcome nor a potential deal is confirmed.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers recent climb to a 52-week high is drawing attention as traders watch for a break above the $30 level, citing product and pipeline progress, including an expanded Tukysa indication and clinical updates. Bulls see a turnaround supported by defensive-sector interest and the dividend, while skeptics question the rallys durability given patent-expiration concerns and resistance near $30.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM is drawing attention as traders position around its Q3 earnings report, with options activity reflecting uncertainty rather than a clear directional consensus. The debate weighs weaker vehicle sales and EV demand against expectations that pricing and product mix could support profitability.

FuelCell Energy, Inc. is an American clean energy technology company that delivers continuous, scalable baseload power for mission-critical applications globally. It engages in the development, design, production, construction, operation, and servicing of high-temperature fuel cells for clean electric power generation. The company’s fuel cell systems generate electricity directly at the point of use, enabling reliable, low-emission power for data centers, industrial facilities, utilities, and distributed generation customers. FuelCell Energy delivers commercially proven, modular, utility-scale systems backed by global fuel cell deployments approaching one gigawatt. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCells Fit Energy data-center project and broader AI-driven demand for on-site power are fueling interest, alongside expectations for a manufacturing ramp and discussion of elevated short interest. Bulls point to the project pipeline and Alex Meruelos reported 7.5% stake, while skeptics question whether opportunities will become firm orders and profitable execution amid dilution and management concerns.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Interim ARO-MAPT data showing substantial tau reduction after a subcutaneous dose has focused attention on whether Arrowheads RNAi platform can deliver treatments across the blood-brain barrier. Many traders view the results as important platform validation, while others are frustrated by the muted share-price response and debate how much value the CNS opportunity merits.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is drawing attention amid a sharp semiconductor pullback and rebound, with traders debating whether AI infrastructure spending and debt-backed data-center expansion can generate adequate returns. Bearish concerns about financing and profitabilityespecially around CoreWeavecontrast with dip-buyers pointing to continued compute demand and Nvidias quantum-computing work.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealths better-than-expected quarterly results and raised full-year outlook, alongside improved medical-cost trends, are driving attention. Bulls view the report as evidence of a turnaround and point to defensive-sector demand, while skeptics note the post-earnings selloff and lingering concerns about Medicare Advantage costs and regulatory risks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Brief Healthcare: PolyPeptide: Strategic Review Is Real, But the Setup Isn’t Clean and more

In this briefing: PolyPeptide: Strategic Review Is Real, But the Setup Isn’t Clean Aequitas: Integris Medtech Ltd Pre-IPO: Medtech Platform with Strong Growth but Elevated Leverage Tetratherix Limited - Commercialising the Platform Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 Primer: Kopran Ltd (KOP IN) - Apr 2026 1. PolyPeptide: Strategic Review Is Real, But the Setup Isn’t Clean PolyPeptide is in a credible strategic review process, but at CHF37.25 the market already prices a 58.3% deal probability, leaving limited upside relative to downside risk in a break scenario. While a full re-rating implies valuation above CHF 50, sponsor return constraints anchor a realistic takeout in the low-to-mid 40s, supported by LBO analysis and peer multiple comparisons. The controlling shareholder structure introduces a third outcome where minorities may not receive a full premium, meaning “a deal” does not necessarily translate into immediate value crystallisation for investors. 2. Aequitas: Integris Medtech Ltd Pre-IPO: Medtech Platform with Strong Growth but Elevated Leverage Integris Medtech Limited (1234518D IN) (IML) plans to raise around US$340m in its upcoming IPO.

Brief Healthcare: Tetratherix Limited - Commercialising the Platform and more

In this briefing: Tetratherix Limited - Commercialising the Platform Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 Primer: Kopran Ltd (KOP IN) - Apr 2026 Sirius (靖因生物) Pre-IPO: Pipeline Prioritization and Competitor Updates TransThera Placement (2617 HK): Tinengotinib Alone Can’t Signal Any Major Upheaval of Fortunes 1. Tetratherix Limited - Commercialising the Platform Tetratherix Limited (ASX:TTX) is an Australian biomedical company commercialising a proprietary polymer platform, Tetramatrix, across four franchises: bone regeneration, tissue spacing, tissue healing and precision medicine. Tetramatrix is a novel fully synthetic, water-based injectable polymer that transitions from a liquid to a solid matrix/scaffold when it enters the human body (at 37°C). As the product mimics natural tissue, it offers potential advantages versus existing animal-derived solutions that are prone to immune responses like inflammation. 2. Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 Solara is a pure-play Active Pharmaceutical Ingredients (API) manufacturer emerging from a significant operational and financial reset, showing early signs of a turnaround with improved profitability and cash flows in the most recent fiscal year.

Brief Equities Bottom-Up: Primer: Arvind Fashions (ARVINDFA IN) - Apr 2026 and more

In this briefing: Primer: Arvind Fashions (ARVINDFA IN) - Apr 2026 Primer: Vedant Fashions (MANYAVAR IN) - Apr 2026 Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 Primer: Sunwoda Electronic Co Ltd A (300207 CH) - Apr 2026 Primer: Kopran Ltd (KOP IN) - Apr 2026 1. Primer: Arvind Fashions (ARVINDFA IN) - Apr 2026 Arvind Fashions holds a strong position in India's apparel market through a focused portfolio of high-recognition, premium, and bridge-to-luxury brands, most notably the licensed brand U.S. Polo Assn., which is a significant revenue driver. The company is pursuing a clear growth strategy centered on expanding its retail footprint via an asset-light franchise model, enhancing its omnichannel capabilities, and growing its direct-to-consumer (D2C) business to improve margins and customer engagement. After a period of portfolio rationalization and financial volatility, the company has shown signs of a turnaround with improving profitability metrics and a strengthened balance sheet, although it faces intense competition and risks associated with licensed brand agreements.

Brief Growth Ideas: Aequitas: Rentmojo Ltd Pre-IPO Tearsheet and more

In this briefing: Aequitas: Rentmojo Ltd Pre-IPO Tearsheet Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 Primer: Sunwoda Electronic Co Ltd A (300207 CH) - Apr 2026 Primer: Kopran Ltd (KOP IN) - Apr 2026 X-Energy Inc. (XE): Amazon Backed Advanced Nuclear Reactor Tech Company Sets Terms for IPO 1. Aequitas: Rentmojo Ltd Pre-IPO Tearsheet Rentmojo Ltd (RMJL IN) s looking to raise about US$126m in its upcoming India IPO. The deal will be run by Axis, IIFL and Motilal Oswal. Rentmojo operates a technology-driven, full-stack direct-to-consumer online rental and subscription platform for furniture and appliances in India, spanning across category management, designing, procurement, refurbishment, servicing, reverse logistics and multi-cycle redeployment. According to Redseer, it was the largest home furniture and appliances online rental and subscription platform(based on live subscribers) as of FY25 and Sep 30, 2025, and subscription revenue(during FY25). 2. Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 Solara is a pure-play Active Pharmaceutical Ingredients (API) manufacturer emerging from a significant operational and financial reset, showing early signs of a turnaround with improved profitability and cash flows in the most recent fiscal year.

Brief India: Aequitas: Rentmojo Ltd Pre-IPO Tearsheet and more

In this briefing: Aequitas: Rentmojo Ltd Pre-IPO Tearsheet Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 Primer: Kopran Ltd (KOP IN) - Apr 2026 Primer: Home First Finance (HOMEFIRS IN) - Apr 2026 HSIE Results Daily: ICICI Prudential Life Insurance Company 1. Aequitas: Rentmojo Ltd Pre-IPO Tearsheet Rentmojo Ltd (RMJL IN) s looking to raise about US$126m in its upcoming India IPO. The deal will be run by Axis, IIFL and Motilal Oswal. Rentmojo operates a technology-driven, full-stack direct-to-consumer online rental and subscription platform for furniture and appliances in India, spanning across category management, designing, procurement, refurbishment, servicing, reverse logistics and multi-cycle redeployment. According to Redseer, it was the largest home furniture and appliances online rental and subscription platform(based on live subscribers) as of FY25 and Sep 30, 2025, and subscription revenue(during FY25). 2. Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 Solara is a pure-play Active Pharmaceutical Ingredients (API) manufacturer emerging from a significant operational and financial reset, showing early signs of a turnaround with improved profitability and cash flows in the most recent fiscal year.

Brief Equities Bottom-Up: Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 and more

In this briefing: Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 Primer: Sunwoda Electronic Co Ltd A (300207 CH) - Apr 2026 Primer: Kopran Ltd (KOP IN) - Apr 2026 Sony Financial Group (8729) - Cheap Vs Peers and Growing Out of Its ROE Hole Primer: Aspial Corp Ltd (ASP SP) - Apr 2026 1. Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 Solara is a pure-play Active Pharmaceutical Ingredients (API) manufacturer emerging from a significant operational and financial reset, showing early signs of a turnaround with improved profitability and cash flows in the most recent fiscal year. The company holds a strong position in several key products, including being a global leader in Ibuprofen, and benefits from a strong regulatory track record with approvals from major authorities like the US FDA and EDQM, which is critical for serving highly regulated markets. High operational gearing, significant historical earnings volatility, and intense competition in the generic API space present considerable risks, but the company's strategic shift towards higher-value products and improving financial health offer potential upside.

Brief India: Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 and more

In this briefing: Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 Primer: Kopran Ltd (KOP IN) - Apr 2026 Primer: Home First Finance (HOMEFIRS IN) - Apr 2026 HSIE Results Daily: ICICI Prudential Life Insurance Company Pharmaceuticals: IPM: 11% growth in Mar-26, 10% in FY26 1. Primer: Solara Active Pharma Sciences (SOLARA IN) - Apr 2026 Solara is a pure-play Active Pharmaceutical Ingredients (API) manufacturer emerging from a significant operational and financial reset, showing early signs of a turnaround with improved profitability and cash flows in the most recent fiscal year. The company holds a strong position in several key products, including being a global leader in Ibuprofen, and benefits from a strong regulatory track record with approvals from major authorities like the US FDA and EDQM, which is critical for serving highly regulated markets. High operational gearing, significant historical earnings volatility, and intense competition in the generic API space present considerable risks, but the company's strategic shift towards higher-value products and improving financial health offer potential upside.

Brief Growth Ideas: Primer: Sunwoda Electronic Co Ltd A (300207 CH) - Apr 2026 and more

In this briefing: Primer: Sunwoda Electronic Co Ltd A (300207 CH) - Apr 2026 Primer: Kopran Ltd (KOP IN) - Apr 2026 X-Energy Inc. (XE): Amazon Backed Advanced Nuclear Reactor Tech Company Sets Terms for IPO Sony Financial Group (8729) - Cheap Vs Peers and Growing Out of Its ROE Hole Sirius (靖因生物) Pre-IPO: Pipeline Prioritization and Competitor Updates 1. Primer: Sunwoda Electronic Co Ltd A (300207 CH) - Apr 2026 Sunwoda is a global leader in lithium-ion batteries, with diversified exposure across consumer electronics (3C), electric vehicles (EV), and energy storage systems (ESS), positioning it to capitalize on broad-based electrification trends. The company exhibits a strong growth trajectory, evidenced by a 3-year revenue CAGR of 14.52% and net income CAGR of 17.05%. However, this growth is capital-intensive, resulting in consistently negative free cash flow and a lower resilience score. Strategic expansion into high-growth EV and ESS markets complements its established leadership in 3C batteries, but the company faces intense competition, margin pressure, and significant operational risks, including supply chain volatility and customer quality disputes.

Brief Equities Bottom-Up: Primer: Kopran Ltd (KOP IN) - Apr 2026 and more

In this briefing: Primer: Kopran Ltd (KOP IN) - Apr 2026 Sony Financial Group (8729) - Cheap Vs Peers and Growing Out of Its ROE Hole Primer: Aspial Corp Ltd (ASP SP) - Apr 2026 Primer: Aspial Lifestyle (ASPL SP) - Apr 2026 Primer: Home First Finance (HOMEFIRS IN) - Apr 2026 1. Primer: Kopran Ltd (KOP IN) - Apr 2026 Kopran is an established, integrated pharmaceutical company with a dual focus on Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDF), leveraging over 60 years of experience. The company has a strong global presence, exporting to over 60 countries. The company's financial performance shows consistent long-term revenue growth, but has been marred by recent margin pressure and a significant decline in 3-year net income and EPS. Negative free cash flow, driven by capital expenditures for capacity expansion, is a key concern. Strategically, Kopran is focused on expanding its API capacity, developing niche products, and reducing its reliance on Chinese raw materials.

Brief Growth Ideas: Primer: Kopran Ltd (KOP IN) - Apr 2026 and more

In this briefing: Primer: Kopran Ltd (KOP IN) - Apr 2026 X-Energy Inc. (XE): Amazon Backed Advanced Nuclear Reactor Tech Company Sets Terms for IPO Sony Financial Group (8729) - Cheap Vs Peers and Growing Out of Its ROE Hole Sirius (靖因生物) Pre-IPO: Pipeline Prioritization and Competitor Updates Primer: Aspial Corp Ltd (ASP SP) - Apr 2026 1. Primer: Kopran Ltd (KOP IN) - Apr 2026 Kopran is an established, integrated pharmaceutical company with a dual focus on Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDF), leveraging over 60 years of experience. The company has a strong global presence, exporting to over 60 countries. The company's financial performance shows consistent long-term revenue growth, but has been marred by recent margin pressure and a significant decline in 3-year net income and EPS. Negative free cash flow, driven by capital expenditures for capacity expansion, is a key concern. Strategically, Kopran is focused on expanding its API capacity, developing niche products, and reducing its reliance on Chinese raw materials.

Kopran Ltd. is a holding company, which engages in the manufacturing of pharmaceuticals and related products. It operates through the following business units: Formulations, and Active Pharmaceutical Ingredients. The firm's products include Amyn, Lokit, and Ciproquin. The company was founded on April 26, 1958 and is headquartered in Mumbai, India.

Current Price	277.30
Prev Close	273.50
Open	270.00
Dividend Yield	2.78%
50-Day Moving Average	241.82
Beta	-0.06
Avg. Volume	2.32M
PE Ratio	53.78

52-Week High	295.83
52-Week Low	107.00
Market Capitalization	13.1B
EPS (Annual)	5.33
Price to Book	2.53
Revenue Per Employee	5.86M

Feed

News

Sentiment

Fundamentals

Info

KOPRAN.NSE Fundamentals